Home>Topics>Stocks>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals REGN

  1. All
  2. Commentary
  3. Headlines
    1. Cramer's Lightning Round - Ensco Is One Of The Worst Stocks I've Owned In My Life (10/17/14)

      Headlines

      Sun, 19 Oct 2014

      way too hard compared to the good fundamentals." Gilead (NASDAQ: GILD ), Celgene (NASDAQ: CELG ), Regeneron (NASDAQ: REGN ): Cramer is bullish on these stocks. Molson Coors (NYSE: TAP ): "It is in the sweet spot. That company could win on any

    2. Amgen sues Sanofi and Regeneron

      Headlines

      Fri, 17 Oct 2014

      suit in the U.S. District Court of Delaware against Sanofi (NYSE: SNY ) ( OTCQB:SNYNF ) and Regeneron Pharmaceuticals (NASDAQ: REGN ) alleging infringement on three of its patents covering monoclonal antibodies to proprotein convertase

    3. Premarket Gainers / Losers

      Headlines

      Fri, 17 Oct 2014

      Gainers: ESI +17% . RADA +12% . IBIO +12% . CYTR +11% . SRPT +9% . TXT +8% . REGN +8% . SUNE +7% . SBGL +6% . NBG +5% . WLT +5% . ACHN +5% . AKS +5% . Losers: RPRX -43% . URBN -14% . PT -6% . Post your comment!

    4. Regeneron's Eylea works better vs Avastin and Lucentis in study

      Headlines

      Fri, 17 Oct 2014

      Oct 17 (Reuters) - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in visual acuity compared with Genentech's Avastin and Lucentis.

    5. Eylea beats Avastin and Lucentis in comparative study

      Headlines

      Fri, 17 Oct 2014

      Institutes of Health and run by the Diabetic Retinopathy Clinical Research Network (DRCR.net), Regeneron's (NASDAQ: REGN ) Eylea (aflibercept) injection demonstrated a significantly greater improvement in mean change in best-corrected visual

    6. Cramer's Lightning Round - You Get Good News From Regeneron (10/16/14)

      Headlines

      Fri, 17 Oct 2014

      the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday October 16. Bullish Calls: Regeneron (NASDAQ: REGN ): "I like Regeneron. It has a backer, it has new drugs, it's the future. That is where you get the good news from

    7. Ohr Pharamceuticals: Stay On The Sidelines

      Headlines

      Fri, 10 Oct 2014

      By Ugly Duckling : Clinical Results Investors in Ohr Pharmaceuticals (NASDAQ: OHRP ) were taken for quite a ride on the heals of the release of interim results of the OHR-102 clinical trial. The stock gyrated as investors tried to balance the failure of the trial to attain its stated endpoint with

    8. Portfolio Changes For The Third Quarter 2014

      Headlines

      Thu, 9 Oct 2014

      Allstate (NYSE: ALL ) CBS Corp. (NYSE: CBS ) Colgate-Palmolive (NYSE: CL ) Oracle (NYSE: ORCL ) Regeneron Pharmaceuticals (NASDAQ: REGN ) Schlumberger (NYSE: SLB ) Wells Fargo (NYSE: WFC ) Viacom (NASDAQ: VIAB ) Walgreen (NYSE

    9. FDA accepts sBLA for Lucentis label expansion

      Headlines

      Wed, 8 Oct 2014

      related macular degeneration, macular edema following retinal vein occlusion and diabetic macular edema. Related tickers: ( REGN -0.4% )( AGN +1.1% )( ALIM +1% )( OTCPK:BAYRY +0.2% )( OTCPK:BAYZF )( PSDV -4.8% ) Post your comment

    10. Rexahn's New Nanotechnology Patent Creates Next-Generation Docetaxel, Gemcitabine And Cisplatin

      Headlines

      Tue, 7 Oct 2014

      By Sharon di Stefano : Targeted cancer therapy is a revolution in drug company research, and Rexahn Pharmaceuticals, Inc. (NYSEMKT: RNN ), recent recipient of a notice of allowance from the US Patent and Trademark Office for a new delivery platform, might one day join the league of bigger players.

    « Prev12345Next »
    Content Partners